Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.43 |
| ▸ | GSK3B | P49841 | 4/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.42 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 3/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.39 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2932352 | 0.84 | GSK3B (0.40) | MAPK14JAK3PIK3CAGSK3BMAPK13 | |
| SCHEMBL1385324 | 0.84 | TOP2A (0.43) | MAPK14PIK3CAGSK3BMAPK13MAPK12 | |
| SCHEMBL1385209 | 0.83 | MAPK14 (0.49) | MAPK14CSNK1DJAK3MAPK13MAPK12 | |
| SCHEMBL1385351 | 0.83 | CDK2 (0.51) | MAPK14CSNK1DJAK3MAPK13MAPK12 | |
| SCHEMBL4057799 | 0.83 | ADORA2A (0.47) | PIK3CAGSK3BGSK3A | |
| SCHEMBL27618729 | 0.82 | PIK3CA (0.41) | MAPK14CSNK1DJAK3PIK3CAGSK3B | |
| SCHEMBL2929634 | 0.80 | MAPK13 (0.46) | MAPK14CSNK1DJAK3GSK3BMAPK13 | |
| SCHEMBL4408117 | 0.79 | MAPK14 (0.47) | MAPK14CSNK1DJAK3PIK3CAGSK3B | |
| SCHEMBL1386407 | 0.76 | MAPK14 (0.52) | MAPK14CSNK1DJAK3MAPK13MAPK12 | |
| SCHEMBL2926468 | 0.75 | MAPK14 (0.48) | MAPK14CSNK1DJAK3MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536194-B2 | Pyrazolopyridine derivates | PALAU PHARMA, S.A. (ES) | 2013-09-17 | — | — | US | claimed |
| EP-1611131-B1 | PYRAZOLOPYRIDINE DERIVATES | PALAU PHARMA SA (ES) | 2010-09-15 | — | — | EP | claimed |
| US-20090005377-A1 | Pyrazolopyridine Derivates | PALAU PHARMA, S.A. (ES) | 2009-01-01 | — | — | US | claimed |
| US-7468376-B2 | Pyrazolopyridine derivates | PALAU PHARMA, S.A. (ES) | 2008-12-23 | — | — | US | claimed |
| CN-100354275-C | Pyrazolopyridine derivates | URIACH Y COMPAGNIA S A J (ES) | 2007-12-12 | — | — | CN | claimed |
| US-20060167040-A1 | Pyrazolopyridine derivates | J. URIACH Y COMPANIA S.A. (ES) | 2006-07-27 | — | — | US | claimed |
| CN-1753894-A | Pyrazolopyridine derivates | URIACH Y COMPAGNIA S A J (ES) | 2006-03-29 | — | — | CN | claimed |
| US-8536194-B2 | Pyrazolopyridine derivates | PALAU PHARMA, S.A. (ES) | 2013-09-17 | — | — | US | disclosed |
| EP-1611131-B1 | PYRAZOLOPYRIDINE DERIVATES | PALAU PHARMA SA (ES) | 2010-09-15 | — | — | EP | disclosed |
| US-20090286983-A1 | Pyrazolopyridine Derivates | PALAU PHARMA, S.A. (ES) | 2009-11-19 | — | — | US | disclosed |
| US-20090005377-A1 | Pyrazolopyridine Derivates | PALAU PHARMA, S.A. (ES) | 2009-01-01 | — | — | US | disclosed |
| US-7468376-B2 | Pyrazolopyridine derivates | PALAU PHARMA, S.A. (ES) | 2008-12-23 | — | — | US | disclosed |
| CN-100354275-C | Pyrazolopyridine derivates | URIACH Y COMPAGNIA S A J (ES) | 2007-12-12 | — | — | CN | disclosed |
| US-20060167040-A1 | Pyrazolopyridine derivates | J. URIACH Y COMPANIA S.A. (ES) | 2006-07-27 | — | — | US | disclosed |
| CN-1753894-A | Pyrazolopyridine derivates | URIACH Y COMPAGNIA S A J (ES) | 2006-03-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167040-A1 | Pyrazolopyridine derivates | MAPK1, MAP4K2, MAP4K3 | MAPK14 34/4885CSNK1D 75/4885JAK3 558/4885 |
| US-20090286983-A1 | Pyrazolopyridine Derivates | MAPK1, MAPK4, MAP4K2 | MAPK14 33/4885CSNK1D 60/4885JAK3 361/4885 |
| US-20090005377-A1 | Pyrazolopyridine Derivates | MAPK1, MAPK4, MAP4K2 | MAPK14 33/4885CSNK1D 60/4885JAK3 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.